Updated · The Atlanta Journal Constitution · May 4
DopFone app enters preclinical trials for at-home fetal monitoring
Updated
Updated · The Atlanta Journal Constitution · May 4
DopFone app enters preclinical trials for at-home fetal monitoring
9 articles · Updated · The Atlanta Journal Constitution · May 4
Georgia Tech professor Alex Adams developed the smartphone-based monitor after his wife Elise’s miscarriages; University of Washington School of Medicine is running early tests, with clinical trials planned within two years.
The app aims to detect fetal heartbeat signals using any smartphone, offering cheaper home monitoring between prenatal visits, though it still needs more testing and US Food and Drug Administration marketing approval.
Experts say it could reassure patients and expand access in underserved areas, but warn misreading results may heighten anxiety. More than 40% of Georgia counties are maternity care deserts.
Will an at-home fetal monitor app truly ease anxiety or just create more panic for parents in remote areas?
Is an app the answer to the maternal health crisis, or a high-tech band-aid for a broken system?
Smartphone-Based DopFone App Validated for Fetal Heart Rate Monitoring Within ±8 bpm Clinical Standard
Overview
As of May 2026, DopFone successfully completed clinical validation under University of Washington oversight, demonstrating high accuracy in estimating fetal heart rate within clinically accepted ranges. Despite this progress, DopFone remains in early clinical stages due to pending FDA approval and regulatory hurdles. The development team is actively addressing key challenges such as performance degradation in noisy environments and with user movement by conducting real-world testing in Atlanta homes. Designed to improve access in maternity care deserts, DopFone is positioned as a supplemental tool that complements professional care, with plans to integrate clinical oversight and enhance user guidance while prioritizing data privacy and security.